We report a successful adaptation of HCS for cytotoxicity using a novel MMP-9/MMP-2i alone and in combination with cisplatin and we provide evidence regarding highly selective MMP-9/MMP-2i involvement in the treatment of ovarian cancer (Figure 7). Here, MMP9 is linked to ovarian cancer.